

Anti-human CD23 Antibody

Catalog Number:	112901, 112902
Size:	25 ug, 100 ug
Target Name:	CD23, Leu-20, IgE Fc Receptor, BLAST-2, Low affinity IgE receptor
Regulatory Status:	RUO

PRODUCT DETAILS

Clone:	EBVCS-5
Application:	Flow Cytometry
Reactivity:	Human
Format:	Purified
Isotype:	Mouse IgG1
Antibody Type:	Monoclonal
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide
Protein Concentration:	0.5 mg/mL
Storage&Handling:	The antibody solution should be stored between 2°C and 8°C
Recommended Usage:	For flow cytometric staining, it is recommended to use less than 0.2 ug of this reagent per 0.5-1.0 million cells in a 100 µL volume. Optimal reagent performance should be determined by titration for each specific application
Isotype Control:	301401

BACKGROUND INFORMATION

CD23, also known as Fc epsilon receptor II (FcεRII), is a low-affinity receptor for immunoglobulin E (IgE) primarily expressed on B cells, as well as on other immune cells such as monocytes, dendritic cells, and some epithelial cells. It plays a key role in regulating IgE-mediated immune responses, including allergic inflammation and antigen presentation. CD23 helps control IgE levels by facilitating the uptake and processing of IgE-bound antigens, thereby influencing both humoral and cellular immunity.

Structurally, CD23 is a type II transmembrane protein belonging to the C-type lectin family. It consists of a short N-terminal cytoplasmic tail, a single transmembrane domain, and a large extracellular region containing a lectin-like head domain responsible for IgE binding. CD23 can also be cleaved by proteases to generate soluble forms (sCD23), which retain biological activity and can modulate immune responses at a distance.

The primary ligand of CD23 is IgE, to which it binds with low affinity compared to the high-affinity FcεRI receptor. CD23 also interacts with other molecules such as CD21 (complement receptor 2) and integrins, contributing to cell adhesion, signaling, and regulation of B cell growth and differentiation. These interactions help coordinate immune responses, particularly in allergic and parasitic conditions.

In disease, CD23 is strongly associated with allergic disorders such as asthma, allergic rhinitis, and atopic dermatitis, where

dysregulated IgE responses play a central role. Elevated levels of soluble CD23 are often observed in these conditions. Additionally, CD23 is a diagnostic marker in certain hematologic malignancies, including chronic lymphocytic leukemia (CLL), where it is highly expressed on malignant B cells.

Therapeutically, CD23 is a target for interventions aimed at modulating IgE-mediated diseases. Strategies include blocking CD23-IgE interactions to reduce allergic inflammation and targeting CD23-expressing cells in malignancies. Ongoing research continues to explore CD23-directed therapies for both allergic and oncologic indications.